Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mikko Gynther

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
European Journal of Pharmacology|April 2, 2016
Effects of the dimeric PSD-95 inhibitor UCCB01-144 in mouse models of pain, cognition and motor functionJesper T Andreasen, Arafat Nasser, Maitane Caballero-Puntiverio, et al.
The Journal of Biological Chemistry|October 24, 2025
A disintegrin and metalloproteinase with thrombospondin motifs 18 (ADAMTS18) cleaves fibronectin and negatively regulates its fibrillogenesisMaria Barbiera, Mikko Gynther, Tetsuya Terasaki, et al.
Pharmaceutical Research|October 19, 2013
Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamineLauri Peura, Kalle Malmioja, Kristiina Huttunen, et al.
Molecular Pharmaceutics|June 11, 2019
Mechanistic Study on the Use of the l-Type Amino Acid Transporter 1 for Brain Intracellular Delivery of Ketoprofen via Prodrug: A Novel Approach Supporting the Development of Prodrugs for Intracellular TargetsElena Puris, Mikko Gynther, Elizabeth C M de Lange, et al.
International Journal of Pharmaceutics|April 19, 2018
Structural properties for selective and efficient l-type amino acid transporter 1 (LAT1) mediated cellular uptakeJussi Kärkkäinen, Mikko Gynther, Tarja Kokkola, et al.
Neuroscience Letters|May 7, 2013
Does increasing the ratio of AMPA-to-NMDA receptor mediated neurotransmission engender antidepressant action? Studies in the mouse forced swim and tail suspension testsJesper T Andreasen, Mikko Gynther, Allan Rygaard, et al.
Scientific Reports|September 8, 2019
L-Type Amino Acid Transporter 1 (LAT1/Lat1)-Utilizing Prodrugs Can Improve the Delivery of Drugs into Neurons, Astrocytes and MicrogliaJohanna Huttunen, Soile Peltokangas, Mikko Gynther, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 9, 2025
Archaeosomal nanocarriers improve pharmacokinetics and bioavailability of vancomycin after oral administrationViktor Sedlmayr, Julian Quehenberger, David Wurm, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|October 13, 2025
Effects of nonsense genetic variants on OATP1B1 expression and transport activity in vitroWilma Kiander, Hatam Rashidpour, Mikko Gynther, et al.
Bioorganic Chemistry|May 2, 2021
Molecular characteristics supporting l-Type amino acid transporter 1 (LAT1)-mediated translocationJussi Kärkkäinen, Tuomo Laitinen, Magdalena Markowicz-Piasecka, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
European Journal of Pharmacology|April 2, 2016
Effects of the dimeric PSD-95 inhibitor UCCB01-144 in mouse models of pain, cognition and motor functionJesper T Andreasen, Arafat Nasser, Maitane Caballero-Puntiverio, et al.
The Journal of Biological Chemistry|October 24, 2025
A disintegrin and metalloproteinase with thrombospondin motifs 18 (ADAMTS18) cleaves fibronectin and negatively regulates its fibrillogenesisMaria Barbiera, Mikko Gynther, Tetsuya Terasaki, et al.
Pharmaceutical Research|October 19, 2013
Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamineLauri Peura, Kalle Malmioja, Kristiina Huttunen, et al.
Molecular Pharmaceutics|June 11, 2019
Mechanistic Study on the Use of the l-Type Amino Acid Transporter 1 for Brain Intracellular Delivery of Ketoprofen via Prodrug: A Novel Approach Supporting the Development of Prodrugs for Intracellular TargetsElena Puris, Mikko Gynther, Elizabeth C M de Lange, et al.
International Journal of Pharmaceutics|April 19, 2018
Structural properties for selective and efficient l-type amino acid transporter 1 (LAT1) mediated cellular uptakeJussi Kärkkäinen, Mikko Gynther, Tarja Kokkola, et al.
Neuroscience Letters|May 7, 2013
Does increasing the ratio of AMPA-to-NMDA receptor mediated neurotransmission engender antidepressant action? Studies in the mouse forced swim and tail suspension testsJesper T Andreasen, Mikko Gynther, Allan Rygaard, et al.
Scientific Reports|September 8, 2019
L-Type Amino Acid Transporter 1 (LAT1/Lat1)-Utilizing Prodrugs Can Improve the Delivery of Drugs into Neurons, Astrocytes and MicrogliaJohanna Huttunen, Soile Peltokangas, Mikko Gynther, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 9, 2025
Archaeosomal nanocarriers improve pharmacokinetics and bioavailability of vancomycin after oral administrationViktor Sedlmayr, Julian Quehenberger, David Wurm, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|October 13, 2025
Effects of nonsense genetic variants on OATP1B1 expression and transport activity in vitroWilma Kiander, Hatam Rashidpour, Mikko Gynther, et al.
Bioorganic Chemistry|May 2, 2021
Molecular characteristics supporting l-Type amino acid transporter 1 (LAT1)-mediated translocationJussi Kärkkäinen, Tuomo Laitinen, Magdalena Markowicz-Piasecka, et al.
Pageof 6